Brokerages Set Arcus Biosciences, Inc. (NYSE:RCUS) Price Target at $21.14

Arcus Biosciences, Inc. (NYSE:RCUS) has been assigned an average recommendation of “Moderate Buy” from the eight brokerages that are presently covering the firm, MarketBeat.com reports. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $21.1429.

Several equities analysts recently commented on RCUS shares. Wall Street Zen upgraded Arcus Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday, August 9th. Wells Fargo & Company dropped their target price on Arcus Biosciences from $26.00 to $25.00 and set an “overweight” rating for the company in a research note on Thursday, August 7th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. CWM LLC boosted its holdings in Arcus Biosciences by 233.6% in the second quarter. CWM LLC now owns 5,441 shares of the company’s stock valued at $44,000 after acquiring an additional 3,810 shares during the last quarter. Lazard Asset Management LLC boosted its holdings in Arcus Biosciences by 3,321.3% in the fourth quarter. Lazard Asset Management LLC now owns 6,261 shares of the company’s stock valued at $93,000 after acquiring an additional 6,078 shares during the last quarter. Ameritas Investment Partners Inc. boosted its holdings in Arcus Biosciences by 34.3% in the second quarter. Ameritas Investment Partners Inc. now owns 7,038 shares of the company’s stock valued at $57,000 after acquiring an additional 1,796 shares during the last quarter. PNC Financial Services Group Inc. boosted its holdings in Arcus Biosciences by 440.3% in the second quarter. PNC Financial Services Group Inc. now owns 7,597 shares of the company’s stock valued at $62,000 after acquiring an additional 6,191 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in Arcus Biosciences by 184.2% in the second quarter. Tower Research Capital LLC TRC now owns 8,449 shares of the company’s stock valued at $69,000 after acquiring an additional 5,476 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Arcus Biosciences Stock Performance

Arcus Biosciences stock opened at $11.50 on Friday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.50 and a current ratio of 4.50. The stock has a fifty day moving average of $10.02 and a two-hundred day moving average of $9.16. The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -3.63 and a beta of 0.83. Arcus Biosciences has a fifty-two week low of $6.50 and a fifty-two week high of $18.98.

Arcus Biosciences (NYSE:RCUS) last released its earnings results on Wednesday, August 6th. The company reported ($1.11) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.03. The firm had revenue of $160.00 million during the quarter, compared to analyst estimates of $32.86 million. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%.The business’s quarterly revenue was up 310.3% compared to the same quarter last year. During the same period in the prior year, the firm posted ($1.02) earnings per share. On average, analysts anticipate that Arcus Biosciences will post -3.15 EPS for the current fiscal year.

Arcus Biosciences Company Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.